XML 28 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
12 Months Ended
Jul. 31, 2019
Jul. 18, 2019
Jan. 03, 2017
Dec. 31, 2017
Dec. 31, 2019
Dec. 31, 2018
Estimated Fair Value            
Goodwill         $ 2,989.6 $ 2,958.0
Aratana Therapeutics, Inc.            
Estimated Fair Value            
Cash and cash equivalents   $ 26.4        
Inventories   10.3        
Other assets and liabilities - net   24.0        
Total identifiable net assets   142.5        
Goodwill   10.8        
Settlement of existing contingent consideration liabilities   84.7        
Total consideration transferred   $ 238.0        
Weighted average useful life   12 years 6 months        
Aratana Therapeutics, Inc. | Acquired in-process research and development            
Estimated Fair Value            
Acquired in-process research and development   $ 31.9        
Aratana Therapeutics, Inc. | Marketed products            
Estimated Fair Value            
Marketed products   36.7        
Aratana Therapeutics, Inc. | Other            
Estimated Fair Value            
Marketed products   $ 13.2        
Prevtec            
Estimated Fair Value            
Cash and cash equivalents $ 0.9          
Property and equipment 0.5          
Other assets and liabilities - net (10.3)          
Total identifiable net assets 53.9          
Goodwill 11.1          
Total consideration transferred $ 65.0          
Weighted average useful life 10 years          
Prevtec | Acquired in-process research and development            
Estimated Fair Value            
Acquired in-process research and development $ 2.8          
Prevtec | Marketed products            
Estimated Fair Value            
Marketed products 58.9          
Prevtec | Other            
Estimated Fair Value            
Marketed products $ 1.1          
BIVIVP            
Estimated Fair Value            
Inventories     $ 108.6      
Property and equipment     148.2      
Marketed products     297.0      
Other assets and liabilities - net     8.2      
Total identifiable net assets     562.0      
Goodwill     320.1      
Total consideration transferred     $ 882.1      
Weighted average useful life     10 years      
BIVIVP | Marketed products            
Estimated Fair Value            
Purchase accounting adjustment       $ 42.7